Carlson Kevin, Civitarese Andrea, Baverstock Richard
vesia [Alberta Bladder Centre], University of Calgary, Calgary, AB, Canada.
Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Can Urol Assoc J. 2017 May;11(5):E179-E183. doi: 10.5489/cuaj.4194. Epub 2017 May 9.
The objective of this study was to compare efficacy and safety outcomes between patients receiving onabotulinum-toxinA (OnabotA) for the first time and those receiving a repeat injection.
Data collected before and after OnabotA injection were extracted from a clinical registry. Patients were classified into either first or repeat injection subgroups. Efficacy was measured by the change in use of oral bladder medications, the number of voids per day or night, the frequency of urinary incontinence (UI) episodes, and patient-reported outcomes. Safety was measured by the number of self-reported complications. Differences in safety measures between the subgroups were tested.
The analysis included complete data from 81 patients; 30 (37%) receiving OnabotA for the first time, 51 (63%) receiving a repeat injection. Both subgroups reported significant reductions in the use of anticholinergics, more tolerable bladder symptoms, and improvements in patient-reported outcomes. Dry rates were similarly high in both groups (50% and 43%, respectively). There were no statistically significant differences between the subgroups in terms of their safety outcomes.
OnabotA is equally as efficacious and safe for patients with overactive bladder receiving a repeat injection as it is for those receiving their first injection.
本研究的目的是比较首次接受A型肉毒杆菌毒素（OnabotA）治疗的患者与接受重复注射的患者的疗效和安全性结果。
从临床登记处提取OnabotA注射前后收集的数据。患者被分为首次注射或重复注射亚组。疗效通过口服膀胱药物使用的变化、白天或夜间排尿次数、尿失禁（UI）发作频率以及患者报告的结果来衡量。安全性通过自我报告的并发症数量来衡量。测试了亚组之间安全措施的差异。
分析包括81例患者的完整数据；30例（37%）首次接受OnabotA治疗，51例（63%）接受重复注射。两个亚组均报告抗胆碱能药物使用显著减少、膀胱症状更易耐受以及患者报告的结果有所改善。两组的干燥率同样较高（分别为50%和43%）。亚组之间在安全性结果方面无统计学显著差异。
对于膀胱过度活动症患者，OnabotA重复注射的疗效和安全性与首次注射相同。
